A Phase 1, Investigator- And Subject-Blind (Sponsor-Open), Randomized, Crossover, Placebo-Controlled Trial To Assess The Safety, Tolerability, And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon [PF-01913539] In Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 23 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.